To the Editor Sun et al¹ conducted a cost-effectiveness analysis of multigene testing among women with breast cancer. The authors state that multiple genetic tests have the potential to reveal more variation (formerly mutation) carriers when an unselected population of patients with breast cancer are targeted and could be more cost-effective in UK and US health systems compared with current family history–based population screenings. This research highlights the importance of screening of an unselected population with breast cancer, which could have an immediate translational influence on patient outcomes. We offer a few suggestions that could help to further strengthen the approach.

致编辑Sun 等人¹对患有乳腺癌的女性进行了多基因检测的成本效益分析。作者指出，当针对未选择的乳腺癌患者群体时，多重基因测试有可能揭示更多变异（以前是突变）携带者，并且与当前基于家族史的卫生系统相比，在英国和美国的卫生系统中可能更具成本效益人口筛查。这项研究强调了筛查未经选择的乳腺癌人群的重要性，这可能对患者的预后产生直接的转化影响。我们提供了一些建议，有助于进一步加强该方法。